Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06548542RecruitingPhase 2
Targeted drug study for moderate to severe Crohn's disease
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Dothan, AlabamaAges 18–75 - NCT06531798RecruitingPhase 4
Safety study of Breztri aerosphere in Indian COPD patients
This study tests a medication called Breztri aerosphere (a triple-combination inhaler) to see how safe and well-tolerated it is in Indian patients with COPD who have had recent flare-ups. It may help people who need better control of their breathing symptoms.
BangaloreAges 18 years+ - NCT06505590Recruiting
Online support for cancer-related fatigue
This trial tests an online support program designed to help people with cancer manage fatigue. If you have had moderate to severe fatigue for at least a week, you may be able to join from home.
VillejuifAges 18 years+ - NCT06485843RecruitingPhase 2
Testing a new injection for moderate to severe knee osteoarthritis
This study tests the safety of an experimental injection called OA-SYS for people with moderate to severe knee osteoarthritis. It may help if you have not had recent injections or certain other health problems.
Las Vegas, NevadaAges 35–75 - NCT06480838Recruiting
Brain blood flow and thinking after traumatic brain injury
This study looks at how the brain controls its own blood flow after a moderate to severe traumatic brain injury (TBI). It uses MRI scans and thinking tests to understand recovery and help improve care for people like you.
Dallas, TexasAges 18–80 - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT06436534Recruiting
Ganciclovir for stubborn allergic rhinitis
This study tests whether an antiviral medicine called ganciclovir (in capsule form) can help people with stubborn moderate-to-severe allergic rhinitis that doesn't improve with standard treatments. If you have year-round allergies to dust mites and your symptoms are still bothersome, this trial may be an option for you.
Wuhan, HubeiAges 18–65 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80 - NCT06420492RecruitingPhase 2
New treatments for severe ulcerative colitis flare
This trial tests new therapies for people with a severe UC flare that hasn't improved after 5 days of high-dose steroids. It aims to find more effective options to control symptoms and avoid hospitalization.
Chestnut Hill, MassachusettsAges 18–75 - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Birmingham, AlabamaAges 18–63 - NCT06397911RecruitingPhase 2
Testing FB825 for moderate to severe eczema
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
Fountain Valley, CaliforniaAges 18–65 - NCT06398626Recruiting
Observational study of etrasimod for ulcerative colitis
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
Mesa, ArizonaAges 18–64 - NCT06396312Recruiting
Predicting lithium response in difficult depression
This study looks at how to predict which people with hard-to-treat depression will benefit from adding lithium to their antidepressant. If you have treatment-resistant depression and are considering lithium, this trial may help find the best treatment for you.
Munich, BavariaAges 18 years+ - NCT06055361RecruitingPhase 1
Studying a new injection for moderate to severe eczema
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
North Little Rock, ArkansasAges 18 years+ - NCT06342440Recruiting
Early detection of colon cancer and advanced polyps
This study aims to find colorectal cancer and advanced polyps (adenomas) earlier by looking at blood samples. Researchers hope a simple blood test might one day help detect colon cancer before it spreads.
Monrovia, CaliforniaAges 18 years+ - NCT06332534RecruitingPhase 3
Upadacitinib in children with moderate to severe Crohn's disease
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Oakland, CaliforniaAges 2–17 - NCT06311682RecruitingPhase 3
Testing a new shot plus steroid cream for children with eczema
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
Birmingham, AlabamaAges 6 months–11 years - NCT06316297RecruitingPhase 1/Phase 2
Testing a new mRNA vaccine for moderate to severe acne
This study tests an experimental mRNA vaccine designed to help the immune system fight acne-causing bacteria. It's for adults with moderate or severe facial acne who are otherwise healthy, and it may offer a new way to treat acne beyond typical creams or pills.
Scottsdale, ArizonaAges 18–45 - NCT06287970Recruiting
Testing a nerve stimulation device for chronic pelvic pain
This trial tests if a non-invasive nerve stimulation device (TaVNS) can reduce pain, urinary symptoms, and mood issues in men with moderate to severe chronic pelvic pain syndrome (CP/CPPS). It may offer a new drug-free option for symptom relief.
Beijing, Beijing MunicipalityAges 18–50 - NCT06282965RecruitingPhase 1/Phase 2
Angiotensin (1-7) for moderate to severe brain injury
This study tests a drug called Angiotensin (1-7) to see if it helps people recover from moderate to severe traumatic brain injury. It may reduce damage and improve healing when given shortly after the injury.
Tucson, ArizonaAges 18 years+ - NCT06257706RecruitingPhase 4
Healing the bowel wall in Crohn's disease with vedolizumab
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
Los Angeles, CaliforniaAges 18–80 - NCT06273995Recruiting
Behavioral activation through telehealth for teens with depression
This trial tests if a telehealth program can help teenagers with depression feel better by increasing positive activities. You and a caregiver will attend weekly video sessions for 8 weeks.
Houston, TexasAges 12–18 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Murrieta, CaliforniaAges 18–75 - NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Lancaster, CaliforniaAges 18–85
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.